Compare CTKB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | FULC |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 468.1M |
| IPO Year | 2021 | 2019 |
| Metric | CTKB | FULC |
|---|---|---|
| Price | $4.85 | $13.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $5.88 | ★ $16.38 |
| AVG Volume (30 Days) | 1.9M | ★ 2.6M |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,828,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $2.37 | $2.32 |
| 52 Week High | $7.30 | $15.74 |
| Indicator | CTKB | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 61.65 |
| Support Level | $4.79 | $12.56 |
| Resistance Level | $5.16 | $15.32 |
| Average True Range (ATR) | 0.24 | 1.27 |
| MACD | -0.11 | 0.30 |
| Stochastic Oscillator | 9.57 | 60.90 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.